{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:55:26Z","timestamp":1792263326259,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Malignant pleural mesothelioma (MPM) is a rare but fatal cancer, which is largely caused by exposure to asbestos. Reliable information about the incidence of MPM prior the influence of asbestos is lacking. The nationwide regional incidence trends for MPM remain poorly characterized. We use nationwide MPM data for Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE) to assess incidence, mortality and survival trends for MPM in these countries.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We use the NORDCAN database for the analyses: incidence data were available from 1943 in DK, 1953 in FI and NO and 1958 in SE, through 2016. Survival data were available from 1967 through 2016. World standard population was used in age standardization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The lowest incidence that we recorded for MPM was 0.02\/100,000 for NO women and 0.05\/100,000 for FI men in 1953\u201357, marking the incidence before the influence of asbestos. The highest rate of 1.9\/100,000 was recorded for DK in 1997. Female incidence was much lower than male incidence. In each country, the male incidence trend for MPM culminated, first in SE around 1990. The regional incidence trends matched with earlier asbestos-related industrial activity, shipbuilding in FI and SE, cement manufacturing and shipbuilding in DK and seafaring in NO. Relative 1-year survival increased from about 20 to 50% but 5-year survival remained at or below 10%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In the Nordic countries, the male incidence trends for MPM climaxed and started to decrease, indicating that the prevention of exposure was beneficial. Survival in MPM has improved for both sexes but long-term survival remains dismal.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08913-2","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T13:02:38Z","timestamp":1636376558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Incidence, mortality and survival in malignant pleural mesothelioma before and after asbestos in Denmark, Finland, Norway and Sweden"],"prefix":"10.1186","volume":"21","author":[{"given":"Kari","family":"Hemminki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asta","family":"F\u00f6rsti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"issue":"9483","key":"8913_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","volume":"366","author":"BW Robinson","year":"2005","unstructured":"Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet (London, England). 2005;366(9483):397\u2013408.","journal-title":"Lancet (London, England)"},{"issue":"7","key":"8913_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00420-019-01433-4","volume":"92","author":"P Boffetta","year":"2019","unstructured":"Boffetta P, Donato F, Pira E, Luu HN, La Vecchia C. Risk of mesothelioma after cessation of asbestos exposure: a systematic review and meta-regression. Int Arch Occup Environ Health. 2019;92(7):949\u201357. https:\/\/doi.org\/10.1007\/s00420-019-01433-4.","journal-title":"Int Arch Occup Environ Health"},{"issue":"2\u20133","key":"8913_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11864-008-0067-z","volume":"9","author":"H Yang","year":"2008","unstructured":"Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options in Oncol. 2008;9(2\u20133):147\u201357. https:\/\/doi.org\/10.1007\/s11864-008-0067-z.","journal-title":"Curr Treat Options in Oncol"},{"issue":"6","key":"8913_CR4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1136\/oem.2005.023200","volume":"63","author":"M Goldberg","year":"2006","unstructured":"Goldberg M, Imbernon E, Rolland P. Gilg Soit Ilg a, Sav\u00e8s M, de Quillacq a, et al. the French national mesothelioma surveillance program. Occup Environ Med. 2006;63(6):390\u20135. https:\/\/doi.org\/10.1136\/oem.2005.023200.","journal-title":"Occup Environ Med"},{"issue":"3","key":"8913_CR5","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1179\/oeh.2003.9.3.206","volume":"9","author":"J Leigh","year":"2003","unstructured":"Leigh J, Driscoll T. Malignant mesothelioma in Australia, 1945-2002. Int J Occup Environ Health. 2003;9(3):206\u201317. https:\/\/doi.org\/10.1179\/oeh.2003.9.3.206.","journal-title":"Int J Occup Environ Health"},{"issue":"8","key":"8913_CR6","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","volume":"11","author":"M Carbone","year":"2016","unstructured":"Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, et al. Consensus report of the 2015 Weinman international conference on mesothelioma. J Thorac Oncol. 2016;11(8):1246\u201362. https:\/\/doi.org\/10.1016\/j.jtho.2016.04.028.","journal-title":"J Thorac Oncol"},{"key":"8913_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2018.07.139","volume":"103","author":"E Kharazmi","year":"2018","unstructured":"Kharazmi E, Chen T, Fallah M, Sundquist K, Sundquist J, Albin M, et al. Familial risk of pleural mesothelioma increased drastically in certain occupations: a nationwide prospective cohort study. Eur J Cancer. 2018;103:1\u20136. https:\/\/doi.org\/10.1016\/j.ejca.2018.07.139.","journal-title":"Eur J Cancer"},{"issue":"12","key":"8913_CR8","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1002\/ijc.25287","volume":"127","author":"SM Mousavi","year":"2010","unstructured":"Mousavi SM, Sundquist J, Hemminki K. Nasopharyngeal and hypopharyngeal carcinoma risk among immigrants in Sweden. Int J Cancer. 2010;127(12):2888\u201392. https:\/\/doi.org\/10.1002\/ijc.25287.","journal-title":"Int J Cancer"},{"issue":"4","key":"8913_CR9","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.21037\/jtd-20-2761","volume":"13","author":"SO Schumann","year":"2021","unstructured":"Schumann SO, Kocher G, Minervini F. Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature. J Thorac Dis. 2021;13(4):2510\u201323. https:\/\/doi.org\/10.21037\/jtd-20-2761.","journal-title":"J Thorac Dis"},{"issue":"52","key":"8913_CR10","doi-asserted-by":"publisher","first-page":"33466","DOI":"10.1073\/pnas.2019652117","volume":"117","author":"A Bononi","year":"2020","unstructured":"Bononi A, Goto K, Ak G, Yoshikawa Y, Emi M, Pastorino S, et al. Heterozygous germline BLM mutations increase susceptibility to asbestos and mesothelioma. Proc Natl Acad Sci U S A. 2020;117(52):33466\u201373. https:\/\/doi.org\/10.1073\/pnas.2019652117.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"8913_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1080\/0284186X.2017.1407039","volume":"57","author":"E Pukkala","year":"2018","unstructured":"Pukkala E, Engholm G, Hojsgaard Schmidt LK, Storm H, Khan S, Lambe M, et al. Nordic Cancer registries - an overview of their procedures and data comparability. Acta Oncol. 2018;57(4):440\u201355. https:\/\/doi.org\/10.1080\/0284186X.2017.1407039.","journal-title":"Acta Oncol"},{"issue":"5","key":"8913_CR12","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1002\/ijc.23230","volume":"122","author":"K Hemminki","year":"2008","unstructured":"Hemminki K, Hussain S. Mesothelioma incidence has leveled off in Sweden. Int J Cancer. 2008;122(5):1200\u20131. https:\/\/doi.org\/10.1002\/ijc.23230.","journal-title":"Int J Cancer"},{"issue":"3\u20134","key":"8913_CR13","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/sj.bjc.6690105","volume":"79","author":"J Peto","year":"1999","unstructured":"Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999;79(3\u20134):666\u201372. https:\/\/doi.org\/10.1038\/sj.bjc.6690105.","journal-title":"Br J Cancer"},{"key":"8913_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/aje\/kwh025","volume":"159","author":"B Price","year":"2004","unstructured":"Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol. 2004;159:107\u201312.","journal-title":"Am J Epidemiol"},{"issue":"5","key":"8913_CR15","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1136\/oem.2003.010165","volume":"61","author":"H Weill","year":"2004","unstructured":"Weill H, Hughes JM, Churg AM. Changing trends in US mesothelioma incidence. Occup Environ Med. 2004;61(5):438\u201341. https:\/\/doi.org\/10.1136\/oem.2003.010165.","journal-title":"Occup Environ Med"},{"issue":"1","key":"8913_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1146\/annurev-publhealth-031811-124704","volume":"34","author":"L Stayner","year":"2013","unstructured":"Stayner L, Welch LS, Lemen R. The worldwide pandemic of asbestos-related diseases. Annu Rev Public Health. 2013;34(1):205\u201316. https:\/\/doi.org\/10.1146\/annurev-publhealth-031811-124704.","journal-title":"Annu Rev Public Health"},{"issue":"1","key":"8913_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ijc.10806","volume":"103","author":"K Hemminki","year":"2003","unstructured":"Hemminki K, Li X. Mesothelioma incidence seems to have leveled off in Sweden. Int J Cancer. 2003;103(1):145\u20136. https:\/\/doi.org\/10.1002\/ijc.10806.","journal-title":"Int J Cancer"},{"issue":"3","key":"8913_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/00008469-200006000-00005","volume":"9","author":"C La Vecchia","year":"2000","unstructured":"La Vecchia C, Decarli A, Peto J, Levi F, Tomei F, Negri E. An age, period and cohort analysis of pleural cancer mortality in Europe. Eur J Cancer Prev. 2000;9(3):179\u201384. https:\/\/doi.org\/10.1097\/00008469-200006000-00005.","journal-title":"Eur J Cancer Prev"},{"issue":"5","key":"8913_CR19","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1080\/02841860902913546","volume":"48","author":"E Pukkala","year":"2009","unstructured":"Pukkala E, Martinsen JI, Lynge E, Gunnarsdottir HK, Sparen P, Tryggvadottir L, et al. Occupation and cancer - follow-up of 15 million people in five Nordic countries. Acta Oncol. 2009;48(5):646\u2013790. https:\/\/doi.org\/10.1080\/02841860902913546.","journal-title":"Acta Oncol"},{"key":"8913_CR20","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2016039","volume":"38","author":"N Plato","year":"2016","unstructured":"Plato N, Martinsen JI, Sparen P, Hillerdal G, Weiderpass E. Occupation and mesothelioma in Sweden: updated incidence in men and women in the 27 years after the asbestos ban. Epidemiol Health. 2016;38:e2016039. https:\/\/doi.org\/10.4178\/epih.e2016039.","journal-title":"Epidemiol Health"},{"issue":"4","key":"8913_CR21","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/01.jom.0000058341.05741.7e","volume":"45","author":"K Hemminki","year":"2003","unstructured":"Hemminki K, Li X. Time trends and occupational risk factors for pleural mesothelioma in Sweden. J Occup Environ Med. 2003;45(4):456\u201361. https:\/\/doi.org\/10.1097\/01.jom.0000058341.05741.7e.","journal-title":"J Occup Environ Med"},{"issue":"5","key":"8913_CR22","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3109\/02841861003782017","volume":"49","author":"G Engholm","year":"2010","unstructured":"Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A, et al. NORDCAN--a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725\u201336. https:\/\/doi.org\/10.3109\/02841861003782017.","journal-title":"Acta Oncol"},{"issue":"5","key":"8913_CR23","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3109\/02841861003631495","volume":"49","author":"HH Storm","year":"2010","unstructured":"Storm HH, Klint A, Tryggvad\u00f3ttir L, Gislum M, Engholm G, Bray F, et al. Trends in the survival of patients diagnosed with malignant neoplasms of lymphoid, haematopoietic, and related tissue in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol. 2010;49(5):694\u2013712. https:\/\/doi.org\/10.3109\/02841861003631495.","journal-title":"Acta Oncol"},{"issue":"5","key":"8913_CR24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3109\/02841861003739322","volume":"49","author":"G Engholm","year":"2010","unstructured":"Engholm G, Gislum M, Bray F, Hakulinen T. Trends in the survival of patients diagnosed with cancer in the Nordic countries 1964-2003 followed up to the end of 2006. Material and methods Acta Oncol. 2010;49(5):545\u201360. https:\/\/doi.org\/10.3109\/02841861003739322.","journal-title":"Material and methods Acta Oncol"},{"issue":"16","key":"8913_CR25","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1016\/j.ejca.2004.07.022","volume":"40","author":"H Brenner","year":"2004","unstructured":"Brenner H, Rachet B. Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases. Eur J Cancer. 2004;40(16):2494\u2013501. https:\/\/doi.org\/10.1016\/j.ejca.2004.07.022.","journal-title":"Eur J Cancer"},{"issue":"6","key":"8913_CR26","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","volume":"6","author":"L Calabr\u00f2","year":"2018","unstructured":"Calabr\u00f2 L, Morra A, Giannarelli D, Amato G, D'Incecco A, Covre A, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 2018;6(6):451\u201360. https:\/\/doi.org\/10.1016\/S2213-2600(18)30151-6.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"8913_CR27","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S2213-2600(18)30176-0","volume":"6","author":"P Baas","year":"2018","unstructured":"Baas P, Disselhorst M. Immuno-oncology in malignant pleural mesothelioma. Lancet Respir Med. 2018;6(6):408\u201310. https:\/\/doi.org\/10.1016\/S2213-2600(18)30176-0.","journal-title":"Lancet Respir Med"},{"issue":"10272","key":"8913_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(20)32714-8.","journal-title":"Lancet"},{"issue":"10","key":"8913_CR29","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","volume":"13","author":"J Quispel-Janssen","year":"2018","unstructured":"Quispel-Janssen J, van der Noort V, de Vries JF, Zimmerman M, Lalezari F, Thunnissen E, et al. Programmed death 1 blockade with Nivolumab in patients with recurrent malignant pleural mesothelioma. J Thoracic Oncol. 2018;13(10):1569\u201376. https:\/\/doi.org\/10.1016\/j.jtho.2018.05.038.","journal-title":"J Thoracic Oncol"},{"issue":"1","key":"8913_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/0284186X.2018.1532599","volume":"58","author":"S Laaksonen","year":"2019","unstructured":"Laaksonen S, Ilonen I, Kuosma E, Sutinen E, Wolff H, Vehmas T, et al. Malignant pleural mesothelioma in Finland: regional and gender variation. Acta Oncol. 2019;58(1):38\u201344. https:\/\/doi.org\/10.1080\/0284186X.2018.1532599.","journal-title":"Acta Oncol"},{"issue":"1","key":"8913_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.5271\/sjweh.3756","volume":"45","author":"V Panou","year":"2019","unstructured":"Panou V, Vyberg M, Meristoudis C, Hansen J, B\u00f8gsted M, Omland \u00d8, et al. Non-occupational exposure to asbestos is the main cause of malignant mesothelioma in women in North Jutland. Denmark Scand J Work Environ Health. 2019;45(1):82\u20139. https:\/\/doi.org\/10.5271\/sjweh.3756.","journal-title":"Denmark Scand J Work Environ Health"},{"issue":"5","key":"8913_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/bjc.1985.105","volume":"51","author":"M Andersson","year":"1985","unstructured":"Andersson M, Olsen JH. Trend and distribution of mesothelioma in Denmark. Br J Cancer. 1985;51(5):699\u2013705. https:\/\/doi.org\/10.1038\/bjc.1985.105.","journal-title":"Br J Cancer"},{"issue":"8","key":"8913_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.20360","volume":"4","author":"Z Zhai","year":"2021","unstructured":"Zhai Z, Ruan J, Zheng Y, Xiang D, Li N, Hu J, et al. Assessment of global trends in the diagnosis of mesothelioma from 1990 to 2017. JAMA Netw Open. 2021;4(8):e2120360. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.20360.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"8913_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1136\/oem.46.2.90","volume":"46","author":"E Raffn","year":"1989","unstructured":"Raffn E, Lynge E, Juel K, Korsgaard B. Incidence of cancer and mortality among employees in the asbestos cement industry in Denmark. Br J Ind Med. 1989;46(2):90\u20136. https:\/\/doi.org\/10.1136\/oem.46.2.90.","journal-title":"Br J Ind Med"},{"issue":"5","key":"8913_CR35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.5271\/sjweh.3879","volume":"46","author":"K Ugelvig Petersen","year":"2020","unstructured":"Ugelvig Petersen K, Pukkala E, Martinsen JI, Lynge E, Tryggvadottir L, Weiderpass E, et al. Cancer incidence among seafarers and fishermen in the Nordic countries. Scand J Work Environ Health. 2020;46(5):461\u20138. https:\/\/doi.org\/10.5271\/sjweh.3879.","journal-title":"Scand J Work Environ Health"},{"key":"8913_CR36","volume-title":"The Third Wave of Asbestos Disease: Exposure to Asbestos in Place. Public Health Control","year":"1991","unstructured":"Landrigan P, Kazemi H, editors. The Third Wave of Asbestos Disease: Exposure to Asbestos in Place. Public Health Control. New York: The New York Academy of Sciences; 1991."},{"issue":"11","key":"8913_CR37","doi-asserted-by":"publisher","first-page":"790","DOI":"10.2471\/BLT.13.132118","volume":"92","author":"T Kameda","year":"2014","unstructured":"Kameda T, Takahashi K, Kim R, Jiang Y, Movahed M, Park EK, et al. Asbestos: use, bans and disease burden in Europe. Bull World Health Organ. 2014;92(11):790\u20137. https:\/\/doi.org\/10.2471\/BLT.13.132118.","journal-title":"Bull World Health Organ"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08913-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08913-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08913-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T13:02:57Z","timestamp":1636376577000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08913-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8913"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08913-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]},"assertion":[{"value":"2 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Aggregated data from a publically accessible database were used posing no ethical issues.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.H. is shareholder in Targovax ASA. A.H. is employee and shareholder in TILT Biotherapeutics Ltd. Other authors declared no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1189"}}